

[For immediate release]



(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 575)

Regent Pacific (0575.HK)'s Deep Longevity Validates BloodAge Model in Major New Study: AI-Powered Biological Age Gap Proven to Predict Long-Term Mortality and Hospitalization Risk

Hong Kong, 30 June 2026 — Regent Pacific Group Limited ("**Regent Pacific**" or the "**Company**" together with its subsidiaries, the "**Group**"; stock code: 0575.HK), is pleased to announce that Deep Longevity, an AI-powered biological aging platform has undergone a new peer-reviewed study published in the leading journal *Aging and Disease*. The study demonstrates that Deep Longevity's proprietary BloodAge model—an AI-driven tool that calculates biological age using only routine blood tests—is a significant, independent predictor of long-term mortality and hospitalization risk.

The study, conducted using nearly a decade of data from the Executive Screening Program at Sheba Medical Center—a globally recognized academic tertiary hospital and the largest and most comprehensive medical facility in Israel and the Middle East—analyzed 2,597 adults age 21-92, generating approximately 23,892 person-years of observation across 6,772 repeated clinical assessments. By utilizing 36 standard blood biomarkers spanning metabolic, hepatic, renal, and inflammatory functions, researchers measured the "Agediff"—the gap between a person's biological age and chronological age.

Key Findings: Emphasize the Predictive Power of "Agediff"

The research conclusively showed that chronological age alone is an insufficient metric for assessing true health risk. According to the data evaluated through Deep Longevity's SenoClock platform:

Elevated Mortality Risk: Each one-year increase in a patient's Agediff was associated with a 15% higher risk of death, even after adjusting for sex, baseline age, BMI, smoking, and hypertension.

Increased Hospitalizations: Each one-year increase in Agediff was linked to a 6% higher rate of hospital admission.

Critical Threshold Identified: Participants whose biological age exceeded their chronological age by 3 years or more experienced a substantially higher cumulative mortality rate over the study period (23.0%) compared to those below the threshold (8.7%).

Democratizing Preventative Healthcare

Historically, comprehensive biological age estimators have relied on costly and complex epigenetics or multi-omic data, making them impractical for routine clinical use. Deep Longevity's BloodAge approach disrupts this paradigm by utilizing standard bloodwork already

collected during routine medical check-ups, thus offering a more accessible way to flag individuals who may be biologically aging faster than their birth date would suggest.

The results from the research represent a massive opportunity for the broader healthcare ecosystem. The researchers noted that the BloodAge model can be deployed without the need for specialised or costly testing such as DNA methylation panels or other multi-omic assays, offering healthcare providers, diagnostic laboratories, and health insurers a highly accessible and scalable tool to identify high-risk individuals early. By utilizing a 3-year Agediff gap as a practical clinical reference point, physicians can implement closer monitoring and risk-mitigation strategies, potentially saving billions in acute care costs associated with chronic aging diseases.

"This landmark study with Sheba Medical Center provides undeniable clinical validation that our AI models can see what the calendar cannot," said **Deepankar Nayak, CEO of Deep Longevity**. "By proving that a simple, routine blood test can reliably predict long-term health outcomes, we are moving longevity science out of the specialized lab and into the everyday clinic. This is a game-changer for preventative medicine, equipping doctors, insurers, and individuals with an accessible, data-driven blueprint for a healthier, longer life."

About the Research

The study, titled "Difference between Biological Age and Chronological Age Predicts Mortality and Hospitalization in a Longitudinal Adult Cohort," was led by Dr. Abigail Goshen of the Sheba Longevity Center, in collaboration with experts from Tel Aviv University, Bar-Ilan University, Shanghai University of Medicine & Health Sciences, and the University of California, Los Angeles.

The BloodAge model is a modular ensemble of 21 deep neural networks trained on over 60,000 blood biochemistry and cell count samples. It is developed and made available globally by Deep Longevity, further cementing the Group's position as a trailblazer in the rapidly expanding longevity economy.

About Deep Longevity

Deep Longevity is an AI-powered biological aging intelligence company dedicated to making healthy aging measurable and actionable. Its proprietary aging clock technology — validated through peer-reviewed science and published in leading international journals — measures biological and cognitive aging across multiple physiological systems, enabling healthcare and consumer health organisations to integrate personalised aging intelligence into their products and services. For more information, visit www.deeplongevity.com.

About Regent Pacific Group Limited (Stock code: 0575.HK)

Regent Pacific is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US\$298 million to shareholders since its initial public offering in May 1997. Recently, the National Medical Products Administration ("NMPA") has officially approved the New Drug Application ("NDA") for Senstend, an innovative treatment for premature ejaculation inclusive of a 4-year data protection period, which became effective on June 10, 2026.

www.regentpac.com

For further information, please contact:

This press release is distributed by LBS Communications Consulting Limited.

For media inquiries, please contact:

Joanne Chan	Tel: (852) 3679 3671	Email: jchan@lbs-comm.com
Jason Ho	Tel: (852) 9836 3448	Email: jho@lbs-comm.com

The English version of this press release shall prevail in case of any discrepancy or inconsistency between the English version and its Chinese translation.